source
- Lilly beats forecasts and raises outlook as Novartis steadies and GSK faces investor pressureLilly reported third‑quarter revenue that exceeded analysts' expectations by about 8%, driven by strong demand for its diabetes and obesity treatments Mounjaro and Zepbound. The company also lifted…
- Eli Lilly lifts guidance by $10 billion as GLP‑1 sales outpace expectationsEli Lilly said its latest financial guidance is $10 billion higher than previously forecast, driven by strong sales of its GLP‑1 medicines. The company’s commercial performance has repeatedly excee…